Saretan 160 mg (Valsartan)
Valsartan 160mg
Tablet · Prescription medication
Alpha Pharmaceutical Co., Ltd.
MFDS item code 201904201 · Approved 2019.06.17
This product's status changed to Expired on 2024.06.17. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Treatment of essential hypertension and heart failure; reduction of the risk of death after myocardial infarction
This medication is used to treat essential hypertension, effectively lowering blood pressure and reducing cardiovascular workload. It is also used in heart failure patients who are intolerant to ACE inhibitors to improve heart function. After myocardial infarction, it helps to reduce the risk of death in stable patients with left ventricular failure or systolic dysfunction. By aiding in the treatment and prevention of various cardiovascular diseases, it contributes to improving the quality of life for patients.
1. Essential hypertension Take with water during a meal or between meals. It is recommended to take this medicine at the same time each day, if possible (e.g., in the morning). 1) Adults: The recommended dose is 80 mg of valsartan orally once daily, regardless of sex or race. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg daily or a diuretic may be coadministered. If further blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. 2) Elderly patients (75 years and older): Initiate treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with 40 mg of this medicine once daily. (3) Creatinine clearance below 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with intravascular volume depletion: For patients with intravascular volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), initiate treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: For patients with mild to moderate hepatic impairment, initiate treatment with 40 mg of this medicine once daily; the dose should not exceed 80 mg daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When administered concomitantly with a diuretic, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, administered in divided doses. Triple combination therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours after the onset of myocardial infarction. The recommended starting dose is 20 mg twice daily. Over the following several weeks, increase the dose, as tolerated by the patient, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytics, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is necessary for patients with creatinine clearance of 10 mL/min or more. However, do not administer this medicine to patients with creatinine clearance below 10 mL/min or patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: For patients with mild to moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If administering 80 mg or more daily, consider whether the benefits of increasing the dose outweigh the risks. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.
The safety and efficacy of this medicine have not been established in children and adolescents under 18 years of age.
This drug can cause serious harm to the fetus if used by pregnant women, thus it must be discontinued immediately if pregnancy is confirmed. It should not be used in individuals allergic to this drug or its components, women who are pregnant or breastfeeding, patients with severely impaired liver or kidney function, and those with certain hereditary angioedema. Caution is needed when using this drug in elderly patients, patients with high potassium levels, patients with impaired liver function, and patients with heart or vascular issues; dosage adjustments or close monitoring of the condition may be necessary. During the course of this medication, side effects such as dizziness, headache, fatigue, cough, and diarrhea may occur, and in rare cases, serious adverse reactions such as angioedema, kidney function impairment, hepatitis may arise. Particular attention is required regarding kidney function changes in patients with heart failure or after myocardial infarction, and regular kidney function tests should be conducted during treatment. This drug may interact with other blood pressure medications, diuretics, and potassium-sparing drugs, so it is essential to inform healthcare providers of any other medications being taken. Dizziness may occur when driving or operating machinery, hence caution is advised. In case of overdose, severe hypotension or loss of consciousness may occur, requiring immediate medical attention, along with possible emergency treatments such as induction of vomiting or volume resuscitation. The safety and efficacy of this medication have not been established in children and adolescents; therefore, its use is not recommended. Store this medication in a place out of the reach of children, and it is advisable not to transfer it to another container.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent exposure to air and moisture, preferably in a cool place below 30 degrees Celsius. This helps maintain the effectiveness of the drug for a longer time.
Oval film-coated tablet in orange with a grayish tint
30 tablets - 30 tablets/bottle, 100 tablets - 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Valsartan 160mg
Tablet · Prescription medication
Alpha Pharmaceutical Co., Ltd.

Valsartan 80mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 160mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 40mg
Tablet · Prescription medication
Samsung Novartis Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan 320mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.